Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2015
At a glance
- Drugs Imatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Methotrexate; Vincristine
- Indications Acute lymphoblastic leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Jul 2014 Status changed from active, no longer recruiting to discontinued. as per M.D. Anderson Cancer Center record.
- 02 Mar 2010 Planned end date changed from Jul 2015 to Mar 2015 as reported by ClinicalTrials.gov.